OP09 Histological remission and mucosal healing in a randomised, placebo-controlled, Phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis
-
- L Peyrin-Biroulet
- University Hospital of Nancy, Vandœuvre-lès-Nancy, France
-
- J Panés
- Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
-
- M Chiorean
- Virginia Mason Medical Center, Seattle, USA
-
- J Zhang
- Arena Pharmaceuticals, Inc., San Diego, USA
-
- S Vermeire
- University Hospitals Leuven, Leuven, Flanders, Belgium
-
- V Jairath
- Western University, London, Ontario, Canada
-
- A Yarur
- Medical College of Wisconsin, Milwaukee, USA
-
- C Cabell
- Arena Pharmaceuticals, Inc., San Diego, USA
-
- S Naik
- Arena Pharmaceuticals, Inc., San Diego, USA
-
- W J Sandborn
- University of California San Diego, La Jolla, USA
この論文をさがす
収録刊行物
-
- Journal of Crohn's and Colitis
-
Journal of Crohn's and Colitis 13 (Supplement_1), S006-S006, 2019-01-25
Oxford University Press (OUP)